[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].

Abstract

AIM:

To evaluate anxiolytic action of GB-115, a low-affinity blocker of central cholecystokinin receptors, used in tablets in a dose of 1 mg for the treatment of patients with anxiety disorders in order to determine effective dose, safety, tolerability and efficacy in clinical settings.

MATERIAL AND METHODS:

The study included 31 patients (22 women, 9 men) diagnosed with generalized anxiety disorder (GAD, F41.1 according to ICD-10), aged from 22 to 53 years. The duration of treatment was 21 days. The Hamilton Anxiety Rating scale, Psychopathologic symptoms severity evaluation scale (PSSES), Spilberger State-Anxiety Inventory, Multidimensional Fatigue Inventory (MFI), Clinical Global Impression scale (CGI), computerized battery for evaluation of cognitive functions ('NS-Psychotest') were used.

RESULTS AND CONCLUSION:

The effective dose of GB-115 was determined at 6 mg per day. Drug action is characterized by fast onset of anxiolytic effect with stimulating properties and beneficial effect on sleep disturbances and autonomic symptoms. GB-115 treatment was associated with favorable changes in attention parameters, reaction time and overall performance. In contrast to first-line drugs for GAD treatment (SSRIs and SNRIs), GB-115 does not induce initial overactivation, anxiety and sleep disturbances. GB-115 is safe and has a good tolerability.

• Authors: G G Neznamov, O A Dorofeeva, M V Metlina, T S Syunyakov, S V Minaev, N Yu Ivashkina, V A Martyanov, S B Seredenin
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 119 Issue 8 Pg. 53-60 ( 2019) ISSN: 1997-7298 [Print] Russia (Federation)
• Vernacular Title: Rezul'taty klinicheskogo issledovaniia novogo anksiolitika, blokatora tsentral'nykh kholetsistokininovykh retseptorov.
• PMID: 31626171 (Publication Type: Journal Article)

Chemical References

• Anti-Anxiety Agents
• Receptors, Cholecystokinin

Topics

• Adult
• Anti-Anxiety Agents (adverse effects, therapeutic use)
• Anxiety Disorders (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Psychiatric Status Rating Scales
• Receptors, Cholecystokinin (antagonists & inhibitors)
• Treatment Outcome
• Young Adult